Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Publication Information:
      MDPI AG, 2021.
    • Publication Date:
      2021
    • Abstract:
      Recombinant protein-based biotherapeutics drugs have transformed clinical pipelines of the biopharmaceutical industry since the launch of recombinant insulin nearly four decades ago. These biologic drugs are structurally more complex than small molecules, and yet share a similar principle for rational drug discovery and development: That is to start with a pre-defined target and follow with the functional modulation with a therapeutic agent. Despite these tremendous successes, this “one target one drug” paradigm has been challenged by complex disease mechanisms that involve multiple pathways and demand new therapeutic routes. A rapidly evolving wave of multispecific biotherapeutics is coming into focus. These new therapeutic drugs are able to engage two or more protein targets via distinct binding interfaces with or without the chemical conjugation to large or small molecules. They possess the potential to not only address disease intricacy but also exploit new therapeutic mechanisms and assess undruggable targets for conventional monospecific biologics. This review focuses on the recent advances in molecular design and applications of major classes of multispecific biotherapeutics drugs, which include immune cells engagers, antibody-drug conjugates, multispecific tetherbodies, biologic matchmakers, and small-scaffold multispecific modalities. Challenges posed by the multispecific biotherapeutics drugs and their future outlooks are also discussed.
    • File Description:
      electronic resource
    • ISSN:
      2073-4468
    • Relation:
      https://www.mdpi.com/2073-4468/10/2/13; https://doaj.org/toc/2073-4468
    • Accession Number:
      10.3390/antib10020013
    • Accession Number:
      edsdoj.5df28ad846a8472eb68b13ef6c7265c2